Fig. 2

B1 asRNA enhances the tumor killing function of lymphocytes in vitro and in vivo. (A) LDH release assay shows that the ability of killing S180 cells of lymphocytes in the B1 asRNA group was higher than that in the PHA group (means of three independent experiments, statistical differences were calculated using one‑way ANOVA with Bonferroni). *P < 0.05. (B) LDH release assay shows that the ability of killing H22 cells of lymphocytes in the B1 asRNA group was higher than that in the PHA group (means of three independent experiments, statistical differences were calculated using one‑way ANOVA with Bonferroni). *P < 0.05. (C) The comparison of the two groups of masses in vivo experiments. (D) In vivo experiments show that tumor weight of the B1 asRNA group was significantly lower than that of the PHA group (mean ± SD of three independent experiments). *P < 0.05.